
    
      PRIMARY OBJECTIVES:Proportion of Patients Who Maintain Weight or Experience Weight Gain.

      SECONDARY OBJECTIVES:BMI Trends, Caloric Intake, Weight Maintenance Over Time, Toxicity
      Profile as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v.4.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive oral
      megestrol acetate 1-2 times (10 mg/kg dose if once daily or 5 mg/kg dose if twice daily)
      daily for 4 weeks. ARM B (control): Patients are observed for weight loss and gain for 4
      weeks. After completion of study treatment, patients are followed up for 12 weeks.
    
  